Navigation Links
MedShift Experiences Notable Growth During First Half-Year Period of 2020

MedShift, a leading medical technology provider, has reported year to date growth of 40% in 2020, despite many obstacles created as a result of COVID-19. As a provider at the forefront of medical technology, MedShift aims to increase revenue for its partnered medical practices and medical manufacturers by expanding access to device offerings, technology services, and marketing solutions. MedShift’s CEO, Brian Phillips, says, “We are quite proud of how much we have accomplished just six months into the year. The beginning of this year provided many obstacles for businesses and agencies everywhere, but we are fortunate to see continued success through this challenging period at MedShift.”

The MedShift engineering team is disrupting the medical device market with the third version of their IoT connected device platform, enabling entire device footprints to report data in real time to improve the quality of device and treatment outputs for practices and manufacturers alike. “The engineering team has developed tremendously in 2020. Since the beginning of this year we have added two new talented developers to our team. We have also established version 3.0 of our IoT connected device hardware/software platform and expanded our e-commerce platform to better service our clients and manufacturers,” says Adam Walsh, Director of Engineering at MedShift.

In 2020 MedShift has been successful in increasing its device portfolio from nine devices to 24. With a 58% increase in devices available through MedShift’s business model in 2020 alone, MedShift aims to help its partners grow through offering a wider array of medical devices to serve the needs of many different medical practices. MedShift has expanded its portfolio to include devices from major manufacturers, including: Rohrer Aesthetics, Merz North America, Sientra/miraDry and Cartessa. “The addition of 15 new devices to our device portfolio allows us to better serve both manufacturers and clients with a more well rounded device line to meet the needs of providers across the country. We are proud to expand our position in the market space through continuous diversification of our device portfolio,” says MedShift’s VP of Sales, Lisa Tiller.

MedShift’s in-house communications agency, MedShift Connect, has seen notable growth in 2020 as well. At the beginning of the year, MedShift Connect began running lead generation campaigns for the medical practices who began their contracts in the 2020 year. MedShift Connect has successfully implemented 46 campaigns and delivered thousands of patients leads in real time to date. By implementing lead generation campaigns, MedShift practices have experienced an increase in treatment interest from potential patients. MedShift Connect has partnered with multiple medical manufacturers in 2020 to drive device sales and improve marketing surrounding the brands both internally and externally. “Our agency size has grown since the beginning of 2020 and we have expanded our client list to include a well rounded roster of clientele. As an agency, we have grown 37% in 2020. Our team has come together to build out a wide variety of deliverables for our clients before, during and after the stay-at-home orders. While COVID-19 has proved challenging to our clients, our team has helped mediate some of the challenges faced by offering additional marketing services, including lead generation. I am excited to see what the remainder of 2020 has in store for both MedShift Connect and MedShift as a whole,” says MedShift’s VP of Communications & Marketing, Victoria Olszowy.

About MedShift -
MedShift, founded in 2015 in Charlotte, NC, delivers a platform as a service to both medical device manufacturers as well as individual medical practices. Foundationally MedShift enables access to the latest devices and technology to remain competitive and attract new business. MedShift has partnered with over 250 providers in North America, Australia, and New Zealand to give practices the latest in cutting-edge treatment modalities, services, and systems.

MedShift is disrupting the traditional aesthetic device market by offering permanent placement, holistic subscription services for surgeons, physicians and their business. MedShift’s broad portfolio of services for practices includes a portfolio of 24 leading aesthetic medical devices from nine manufacturers, an aesthetic eCommerce and subscription platform, in-house communications and marketing services, and inbound lead generation. For manufacturers Medshift delivers a highly secure IoT platform consisting of both hardware and software assets allowing for real time visibility, remote management, and big data modeling of entire medical device lineups. MedShift adds value across the manufacturer and provider spectrum and continues to empower robust integration with the leading brands and doctors in the industry.

Read the full story at

Source: PRWeb
Copyright©2020 Vocus, Inc.
All rights reserved

Related biology technology :

1. Blood Centers of America Experiences Record Growth
2. SonaCare Medical's Sonablate® Prostate HIFU Procedure Experiences High Demand upon Entering Miami
3. Biopharma Leaders Unite to Share Real-Life Business Development Experiences at LeadingBiotech’s Boston BD Conference
4. Fumio Hirakawa has been awarded with the notable Golden A' Design Award
5. Notable Labs Enters into a Collaboration Agreement with IntelliCyt to Develop a Phenotypic Personalized Medicine Platform for Cancer Patients
6. Bioengineered Skin Substitutes to 2016. Products, Players, Markets and Growth Prospects
7. Lucintel's Analysis of Global Catalysts Industry: Chemical and Automobile Industries Play Crucial Role in Growth
8. Diversified Pipeline and Low Threat of Biosimilar Sales Erosion To Drive Growth Of Monoclonal Antibodies Market
9. Will Safety Concerns Slow Nanotechnology Drug Delivery Market Growth? Forecasts Predict 84.79% Growth in US, 73.97% Globally through 2016
10. Medical Marijuana Inc., Corporate Update- Significant Revenue and Net Income Growth 1st Quarter- Division and Corporate Holdings Update
11. Nerium International Receives the 2012 Global 100 Bravo Award for Growth
Post Your Comments:
(Date:7/31/2020)... ... July 29, 2020 , ... Editas Medicine, Inc. ... of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and ... a strategic partnership whereby Catalent will provide support for the development, manufacturing, and ...
(Date:7/22/2020)... ... July 22, 2020 , ... Join experts from Reed ... Manager Regulatory Solutions, in a one hour live webinar on Thursday, August ... in China for drugs and medical devices. Specifically, for medical devices, the NMPA has ...
(Date:7/18/2020)... ... July 17, 2020 , ... dicentra , ... sciences and food industries, is pleased to announce that Charles Galea has joined ... Development. , Charles is an accomplished and results-driven sales executive with over 10 ...
(Date:7/10/2020)... Mass. (PRWEB) , ... July 09, 2020 , ... ... approaches to cell therapy, today announced the hiring of Allen R. Nissenson, M.D., ... team and oversee the clinical development of Sentien’s lead product, SBI-101. Dr. ...
Breaking Biology Technology:
(Date:9/3/2020)... ... September 03, 2020 , ... ... that an extensive third-party assessment of the company’s security practices has been completed. ... federal security regulations. The comprehensive evaluation reviewed Litmus’ processes and systems, assessing them ...
(Date:8/26/2020)... ... August 25, 2020 , ... ... in partnership with Essex Bio-Technology, a bio-pharmaceutical company specializing in Ophthalmology and ... study of SkQ1 ophthalmic solution in patients with moderate to severe Dry ...
(Date:8/26/2020)... ... , ... Modality Solutions, a biopharmaceutical cold chain validation engineering firm, ... list is the most prestigious ranking of the nation’s fastest-growing private companies. Modality Solutions ... reported three-year revenue growth of 71 percent. , The Inc. 5000 list represents ...
Breaking Biology News(10 mins):